Chris Compton
GlaxoSmithKline (United Kingdom)(GB)General Medical Council(GB)
Publications by Year
Research Areas
Chronic Obstructive Pulmonary Disease (COPD) Research, Asthma and respiratory diseases, Respiratory Support and Mechanisms, Inhalation and Respiratory Drug Delivery, Respiratory and Cough-Related Research
Most-Cited Works
- → Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial(2019)232 cited
- → Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial(2019)123 cited
- → INTREPID: single-versusmultiple-inhaler triple therapy for COPD in usual clinical practice(2021)67 cited
- → Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials(2025)58 cited
- → Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting(2022)45 cited
- → Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD(2021)40 cited
- → Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis(2022)38 cited
- → Preventing clinically important deterioration with single-inhaler triple therapy in COPD(2018)25 cited
- → Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial(2020)19 cited
- → Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial(2022)17 cited